23:47:42 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-02-29 Bokslutskommuniké 2023
2023-11-23 Kvartalsrapport 2023-Q3
2023-08-25 Kvartalsrapport 2023-Q2
2023-06-30 Årsstämma 2023
2023-05-31 Kvartalsrapport 2023-Q1
2023-05-05 Ordinarie utdelning RLS 0.00 SEK
2023-02-28 Bokslutskommuniké 2022
2023-02-09 Extra Bolagsstämma 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-20 Ordinarie utdelning RLS 0.00 SEK
2022-05-19 Årsstämma 2022
2022-05-11 Kvartalsrapport 2022-Q1
2022-02-25 Bokslutskommuniké 2021
2021-11-12 Kvartalsrapport 2021-Q3
2021-07-16 Kvartalsrapport 2021-Q2
2021-06-17 Årsstämma 2021
2021-05-27 Ordinarie utdelning RLS 0.00 SEK
2021-05-07 Kvartalsrapport 2021-Q1
2021-02-10 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-07-17 Kvartalsrapport 2020-Q2
2020-05-27 Ordinarie utdelning RLS 0.00 SEK
2020-05-26 Årsstämma 2020
2020-05-15 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-15 Kvartalsrapport 2019-Q3
2019-08-19 Extra Bolagsstämma 2019
2019-08-15 Kvartalsrapport 2019-Q2
2019-05-31 Ordinarie utdelning RLS 0.00 SEK
2019-05-29 Årsstämma 2019
2019-05-15 Kvartalsrapport 2019-Q1
2019-02-28 Bokslutskommuniké 2018
2018-11-30 Kvartalsrapport 2018-Q3
2018-08-31 Kvartalsrapport 2018-Q2
2018-06-14 Ordinarie utdelning RLS 0.00 SEK
2018-06-13 Årsstämma 2018
2018-05-31 Kvartalsrapport 2018-Q1
2018-02-28 Bokslutskommuniké 2017
2017-11-28 Kvartalsrapport 2017-Q3
2017-11-15 Extra Bolagsstämma 2017
2017-08-31 Kvartalsrapport 2017-Q2
2017-06-09 Ordinarie utdelning RLS 0.00 SEK
2017-06-08 Årsstämma 2017
2017-05-31 Kvartalsrapport 2017-Q1
2017-02-20 Bokslutskommuniké 2016
2016-11-30 Kvartalsrapport 2016-Q3
2016-08-31 Kvartalsrapport 2016-Q2
2016-06-01 Ordinarie utdelning RLS 0.00 SEK
2016-05-31 Kvartalsrapport 2016-Q1
2016-05-31 Årsstämma 2016
2016-02-29 Bokslutskommuniké 2015
2016-01-21 Extra Bolagsstämma 2016
2015-11-30 Kvartalsrapport 2015-Q3
2015-08-31 Kvartalsrapport 2015-Q2
2015-06-12 Ordinarie utdelning RLS 0.00 SEK
2015-06-11 Årsstämma 2015
2015-05-28 Kvartalsrapport 2015-Q1
2015-02-27 Bokslutskommuniké 2014
2014-11-28 Kvartalsrapport 2014-Q3
2014-09-12 Extra Bolagsstämma 2014
2014-08-29 Kvartalsrapport 2014-Q2
2014-06-10 Ordinarie utdelning RLS 0.00 SEK
2014-06-09 Årsstämma 2014
2014-05-23 Kvartalsrapport 2014-Q1
2014-03-05 Bokslutskommuniké 2013
2013-11-29 Kvartalsrapport 2013-Q3
2013-09-04 Kvartalsrapport 2013-Q2
2013-05-31 Kvartalsrapport 2013-Q1
2013-05-08 Split RLS 10:1
2013-04-11 Ordinarie utdelning RLS 0.00 SEK
2013-04-10 Årsstämma 2013
2013-03-05 Bokslutskommuniké 2012
2012-11-26 Kvartalsrapport 2012-Q3
2012-08-31 Kvartalsrapport 2012-Q2
2012-06-12 Ordinarie utdelning RLS 0.00 SEK
2012-06-11 Årsstämma 2012

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
RLS Global är verksamma inom bioteknik. Bolaget utvecklar biokemiska produkter och metoder för behandling av förekommande sår hos patienter. Bolagets produkter angriper skadad vävnad via den egenutvecklade teknologin som baseras på hypoklorit. Idag bedrivs forskning och utveckling inom vävnadsbaserad teknik. Bolaget har sitt huvudkontor i Göteborg.
2023-02-28 08:30:00
OCTOBER 1st - DECEMBER 31st (previous year in brackets)
  • Net sales amounted to TSEK 291 (TSEK 219)
  • Earnings before interest and taxes (EBIT) amounted to MSEK -7,9 (MSEK -7,8)
  • Earnings per share after dilution at SEK -0,10 (SEK 0,09)
  • Cash flow from operating activities amounted to TSEK -5 779 (TSEK -4 887)
  • Liquid assets at the end of the period MSEK 20,5 ( MSEK 11,5)
  • Equity ratio was 83 % (75 %)
JANUARY 1st - DECEMBER 31st (previous year in brackets)
  • Net sales amounted to TSEK 1 198 (TSEK 653)
  • Earnings before interest and taxes (EBIT) amounted to MSEK -24,3 (MSEK 11,0)
  • Earnings per share after dilution at SEK -0,3 (SEK- 0,14)
  • Cash flow from operating activities amounted to TSEK -23 569 (TSEK -8 353)
  • Liquid assets at the end of the period MSEK 20,5 (MSEK 11,5)
  • Equity ratio was 83 % (75 %)
SUMMARY OF EVENTS DURING FIRST QUARTER
  • RLS Global's notified bodies perform quality audits (ISO 13485 and MDD) without remarks
  • Karin Fischer hands in her resignation
  • Convatec is taking over the agreements with Swedish customers
  • ChloraSolv is now delivered to the Convatec central warehouse on a regular basis
  • ChloraSolv is reimbursed in the Netherlands
SUMMARY OF EVENTS DURING SECOND QUARTER
  • Annual General Meeting is held May 19
  • RLS signs distribution contract for Middle East
  • RLS introduces ChloraSolv for the animal segment in Scandinavia by signing distribution contract with Swevet
  • ChloraSolv is approved for leg ulcers in Kuwait
SUMMARY OF EVENTS DURING THIRD QUARTER
  • An article regarding ChloraSolv is published in Journal of Wound Care
  • RLS Global strengthens its solvency by transforming a loan to share capital

 

SUMMARY OF EVENTS DURING FOURTH QUARTER
  • Björn Larsson starts as CEO
  • RLS carries out a new share issue (rights issue) and thereby raises SEK 26.8 million in cash and cash equivalents after issue costs
  • The Swedish Medicines Agency approves RLS' application for a clinical study regarding pressure ulcers
  • RLS takes part in the conference Wounds UK in Harrogate, England
SUMMARY OF EVENTS AFTER FOURTH QUARTER
  • An extra General Meeting is held February 9, 2023
  • Lars Johansson is elected as Chairman of the Board
  • RLS visits Arab Health, a global health conference in the Middle East and performs on-site distributor meetings and training sessions

The Year-end Report Q4, 2022, is enclosed and is also available here. (https://rls.global/wp-content/uploads/2023/02/RLS_Global_Q4_2022_EN.pdf)

Publication
This information was submitted for publication through the agency of the below contact person, at 08.30 CET on Feb 28th 2023.